To protect against human immunodeficiency virus (HIV-1) infection, broadly neutralizing antibodies (bnAbs) must be active at the portals of viral entry in the gastrointestinal or cervicovaginal tracts. The localization and persistence of antibodies at these sites is influenced by the neonatal Fc receptor (FcRn) 1, 2 , whose role in protecting against infection in vivo has not been defined. Here, we show that a bnAb with enhanced FcRn binding has increased gut mucosal tissue localization, which improves protection against lentiviral infection in non-human primates. A bnAb directed to the CD4-binding site of the HIV-1 envelope (Env) protein (denoted VRC01) 3 was modified by site-directed mutagenesis to increase its binding affinity for FcRn. This enhanced FcRn-binding mutant bnAb, denoted VRC01-LS, displayed increased transcytosis across human FcRn-expressing cellular monolayers in vitro while retaining FccRIIIa binding and function, including antibody-dependent cell-mediated cytotoxicity (ADCC) activity, at levels similar to VRC01 (the wild type). VRC01-LS had a threefold longer serum half-life than VRC01 in non-human primates and persisted in the rectal mucosa even when it was no longer detectable in the serum. Notably, VRC01-LS mediated protection superior to that afforded by VRC01 against intrarectal infection with simian-human immunodeficiency virus (SHIV). These findings suggest that modification of FcRn binding provides a mechanism not only to increase serum half-life but also to enhance mucosal localization that confers immune protection. Mutations that enhance FcRn function could therefore increase the potency and durability of passive immunization strategies to prevent HIV-1 infection.
Antibody protection against viral infection is influenced by effector functions mediated by the Fc domain of the antibody interacting with activating Fc receptors (including FccRIIIa-mediated ADCC 4 ) or inhibitory Fc receptors on the surface of immune cells 5 . FcRn is a multifunctional receptor that plays a role in IgG transport and homeostasis 1, 2 . FcRn binds to the Fc portion of IgG with high affinity at an acidic pH (,6.5) . Following endocytosis, free IgG is degraded in the lysosome, while FcRn-bound IgG avoids degradation at low pH and is recycled into the extracellular space, thus prolonging the half-life of IgG 1, 2 . Recently, several monoclonal antibodies with broad and potent neutralizing activity against diverse HIV-1 Env proteins have been shown to confer passive protection against SHIV infection 3, [6] [7] [8] [9] [10] [11] 29 . To determine whether the protective efficacy of such antibodies can be increased by modulation of FcRn effector function, we evaluated the role of mutations that increase binding to FcRn. To potentiate the effector function of the bnAb VRC01, we introduced mutations in the CH2 and/or CH3 domains of VRC01 and analysed the binding affinity of these mutated antibodies for human FcRn and FccRIIIa. Five mutants known to enhance binding to human FcRn (Fig. 1a) , along with a non-FcRn-binding mutant (IHH) [12] [13] [14] [15] [16] , were characterized in vitro. Similarly to VRC01, all mutants bound to a previously described HIV-1 Env protein, RSC3 (which consists of a resurfaced, stabilized core 3 of HIV-1 glycoprotein (gp) 120) (Fig. 1b) ; this finding is consistent with previously published reports of the effects of these FcRn-binding mutations on other IgGs 14 . All mutants also had similar neutralization potency and breadth to VRC01 (Extended Data Table 1 ). These data confirm that the FcRn-binding mutations did not interfere with the recognition of cognate antigen or with neutralization.
We also compared the ability of the FcRn-binding mutants to bind to human FcRn at physiological or endosomal pH (7.4 and 6.0, respectively). As expected, all mutants except VRC01-IHH bound more strongly to FcRn at either pH than did VRC01 (Fig. 1c) . While the binding of the Fc mutants to human FcRn at pH 7.4 by enzyme-linked immunosorbent assay (ELISA) was greater than that of VRC01 at saturating antibody concentrations (.10 mg ml 21 ), differences in binding potency are best discriminated by using half-maximum binding concentrations (EC 50 ). Analysis of EC 50 values revealed greater binding by each of the FcRnenabled mutants at pH 6.0 than at pH 7.4 (Extended Data Table 2 ), as expected and consistent with previous reports on the pH dependence of FcRn binding. It has been proposed that higher affinity binding to FcRn at pH 7.4 might inhibit the release of FcRn-bound IgG 17 . The FcRn-binding mutants of VRC01 were dissociated at pH 7.4 similar to VRC01 (Extended Data Fig. 1 ), indicating that VRC01 FcRn-binding mutations enhanced the pH-dependent binding but did not affect release at physiological pH.
FcRn affects the transport of IgG from the basolateral to the apical surface of mucosal epithelial cells 1 . We therefore compared the transport of VRC01 and its FcRn-binding mutants across MDCK (MadinDarby canine kidney) cells that express human FcRn and b 2 -microglobulin in a transwell system in vitro. When the concentration of monoclonal antibodies in the upper (apical) chamber was measured 2 h after antibody addition to the lower (basolateral) chamber, the transcytosis of all mutants with enhanced FcRn binding was at least 2.5-fold higher than that of VRC01. The highest level of transcytosis was exhibited by the VRC01-LS and VRC01-YTE mutants (Fig. 1d) . These results show that mutations which enhance FcRn binding increase the transport of VRC01 in a functional cell culture system. To confirm this effect in vivo, we evaluated the pharmacokinetics of these antibody mutants in human FcRn-transgenic mice 18 (n 5 4 per group). Similar to the cell culture results, all mutants with enhanced binding to human FcRn had a longer half-life than VRC01 (Extended Data Fig. 2) .
In addition to virus neutralization, another Fc effector function has been implicated in immune protection. ADCC, which is mediated by IgG binding to FccRIIIa, can lyse infected cells 4, 19 . Because enhanced FcRn-binding mutations might affect the interactions of IgG with FccRIIIa and thereby alter ADCC activity 13 , we assessed the FccRIIIa binding and ADCC effector function of each mutant. We performed ELISA binding assays with human FccRIIIa and ADCC assays using human peripheral blood mononuclear cells as effector cells and HIV-infected CEM-NK R cells (a natural killer (NK)-cell-resistant human T leukaemia cell line) as targets 20 . Most of the enhanced FcRn-binding mutants showed lower FccRIIIa binding and ADCC activity than VRC01. Interestingly, only the VRC01-LS mutant exhibited both FccRIIIa binding and ADCC activity comparable to VRC01 (Fig. 1e, f) . We further examined the binding affinities of VRC01-LS for human FcRn and FccRIIIa using surface plasmon resonance analysis. Consistent with the ELISA results, VRC01-LS exhibited a 12-fold higher human FcRn binding affinity than VRC01, whereas both displayed similar binding to human FccRIIIa (Table 1) . These data suggested that the increased FcRn binding of VRC01-LS did not affect its FccRIIIa-mediated effector function. We further examined the binding of these VRC01 variants to two other functional IgG receptors, FccRIIa and FccRIIb. We found no difference in the binding of VRC01 and VRC01-LS to either receptor, as determined by ELISA (Extended Data Fig. 3 ), suggesting that VRC01-LS does not differ from VRC01 with respect to ADCC effector function or immune suppression through FccRIIa or FccRIIb, respectively.
Because its ADCC activity was not affected by the FcRn-binding mutation, we selected the VRC01-LS mutant for further analysis in nonhuman primates. Its half-life in vivo was evaluated by injection (10 mg per kg body weight) and compared with VRC01, and VRC01-IHH, in Indian rhesus macaques (Macaca mulatta). The serum concentrations of each monoclonal antibody were measured by ELISA, and the half-lives were calculated using a two-compartment model (Fig. 2a) ). By contrast, VRC01-IHH displayed markedly less persistence than the wild type, with a half-life of ,1 day. This result confirmed that the increase in FcRn binding of VRC01-LS prolonged the antibody's half-life in non-human primates.
Since the gut mucosa is a primary site of HIV infection, we examined the accumulation of each monoclonal antibody in the rectal mucosa. Because direct tissue immunohistochemical staining is subject to sampling variation, we used a more quantitative approach: we quantified the total amount of VRC01 or VRC01-LS in rectal tissue homogenates, by using ELISA. Protein was extracted from rectal biopsy samples, and the amount of each monoclonal antibody was normalized to the total amount of tissue protein. After a single injection (10 mg kg 21 ), VRC01-LS remained detectable in rectal tissue for more than 70 days and persisted at significantly higher levels than VRC01 (P , 0.001, two-tailed t-test), which was not detected after 28 days (Fig. 2b ). VRC01-IHH was not detected in rectal tissues after 14 days. At lower concentrations of monoclonal antibody (0.3 mg kg 21 ), a similar trend was seen in both the serum and the rectal mucosa. The levels of VRC01 in rectal tissue peaked at day 2, whereas VRC01-LS continued to increase up to day 5, after which it persisted at higher levels than VRC01 (Fig. 3a) . In parallel studies, we also compared the relative monoclonal antibody levels in rectal secretions and tissue in cynomolgus macaques (Macaca fascicularis). Similarly to rhesus macaques, VRC01-LS circulated for threefold longer in the serum than did VRC01 (Extended Data Fig. 4a ). Compared with VRC01, higher levels of VRC01-LS were measured in both rectal secretions and tissue at 28 days post antibody infusion, although the rectal tissue sampling was more consistent than the secretions (Extended Data Fig. 4b, c) . We therefore suggest that tissue IgG provides an important indicator of mucosal IgG localization, consistent with a previous report 21 .
To determine whether VRC01 co-localized with FcRn in vivo, rectal biopsy samples taken after a single injection were stained either with a polyclonal antibody specific for human FcRn or with an HIV-1 Env probe, RSC3 (ref. 3) . FcRn co-localized with VRC01 mainly in mucosal epithelial cells (Fig. 2c) . Together, these data demonstrated that VRC01-LS persisted longer in the serum than VRC01 and accumulated in the mucosa as a result of its increased binding affinity for FcRn. 
LETTER RESEARCH
To determine whether VRC01-LS can protect against infection more effectively than VRC01, we performed an intrarectal challenge with the CC-chemokine receptor 5 (CCR5)-tropic SHIV BaLP4. Rhesus macaques (n 5 12 per group) were injected intravenously with a low, suboptimally protective, dose (0.3 mg kg 21 ) of VRC01, VRC01-LS or control IgG and challenged intrarectally with SHIV 5 days after passive antibody transfer. All control-IgG-injected macaques became infected within 3 weeks of SHIV challenge, as measured by plasma viraemia. Ten of 12 macaques that received VRC01 were infected, in contrast to 5 of 12 VRC01-LS-injected macaques (P 5 0.0447, one-tailed Fisher's exact test) (Fig. 3b and Extended Data Fig. 5 ). Among the infected animals, no significant differences in peak or set-point viraemia were observed between these experimental groups. VRC01-LS therefore conferred superior protection to VRC01 against acquisition of lentiviral infection.
In this study, we show that modification of a monoclonal antibodyFcRn interaction through mutations in the Fc domain can increase the protection afforded by the antibody against mucosal lentiviral challenge.
Passive infusion of anti-HIV-1 bnAbs has been shown to prevent mucosal SHIV infection 22 , and the pharmacokinetics and biodistribution of the bnAbs play important roles in this protection 21 ; however, the mechanism that confers mucosal protection has not been defined. Specifically, whether antibody transport and FcRn effector function contribute to mucosal immunity in primates was previously unknown. Our work demonstrates that FcRn plays an important role in IgG transport and provides insight into the mechanism by which FcRn function facilitates protection by IgG against mucosal viral infection. The increased FcRn binding of IgG induced by the LS mutation avoids endosomal degradation, allowing recycling into the serum, thereby increasing the serum antibody levels. The antibody retention in the rectal mucosa is probably due to antibody sequestration in the endosomes of epithelial cells (as indicated by the intracellular localization, Fig. 2c ), which is presumably followed either by recycling into the subepithelial mucosal tissue for interactions with professional antigen presenting cells or by transcytosis into the intestinal lumen. Importantly, this mutation also increased the retention of IgG in the intestinal mucosa at the portal of HIV-1 entry, where a higher local concentration can more effectively neutralize local infection.
Our results suggest that active, FcRn-mediated transport, as opposed to simple diffusion, is a major component of IgG compartmentalization in the mucosal tissues of the rectum. FcRn-mediated transport of IgG to mucosal surfaces may play an unrecognized role in the ability of a variety of vaccines to successfully block mucosal viral infections. For example, vaccination with inactive poliovirus (also known as the Salk vaccine) generates an IgG response that can block poliovirus infection in the gut mucosa 23 . There are similarities, as well as potential differences, between poliovirus and HIV-1 pathogenesis. Both poliovirus and HIV-1 invade the human body through mucosal tissues, especially the intestinal mucosa, but the receptors for cell entry are different. Poliovirus penetrates the body through M cells, in the Peyer's patches 24 , whereas HIV-1 targets intraepithelial CD4
1 T cells in the mucosal epithelium. Although FcRn mediates the transcytosis of IgG across the intestinal epithelium in vivo as has been shown in a humanized mouse model 25 , our results demonstrate that FcRn is also a means to retain IgG in tissues. This latter effect may restrain the quantities of IgG that are transported into the lumen and potentially explains why previous studies have failed to find an association between monoclonal antibody levels in mucosal secretions and protection 21 . Macaques with higher levels of bnAbs (VRC01-LS) in rectal tissues had a lower rate of infection than macaques injected with VRC01 (Fig. 3) . Thus, it is important to measure IgG in tissues, in addition to in mucosal secretions. 
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; area under the curve (AUC), 632 versus 1,645 day 3 mg ml
). b, The amount of monoclonal antibody per mg of total tissue protein in rectal biopsy samples from each monoclonal-antibody-injected rhesus macaque (n 5 4 per group) was quantitated and is shown over time. VRC01-LS persisted at higher levels than did VRC01 (P , 0.001, two-tailed t-test). The data points are the mean 6 s.e.m. c, Immunohistochemical staining of the rectal biopsy samples (n 5 6 at 10 or 20 mg kg 21 dose) after VRC01 administration shows co-localization of VRC01, as measured by indirect binding to an Env probe, RSC3 (VRC01, red; top) and FcRn, stained with an anti-human FcRn polyclonal antibody (FcRn, red; bottom). The sections shown are representative of those observed in the six macaques. The adjacent sections were stained with RSC3 and the anti-human FcRn polyclonal antibody in test samples. Buffer without RSC3 and control rabbit IgG were used as negative controls for VRC01 and FcRn staining, respectively. The arrows indicate VRC01 or FcRn staining in the cytoplasm of epithelial cells. The images were captured at 320 original magnification, except for the right column, which shows magnified views of the centre column (340 original magnification). 
RESEARCH LETTER
The sexual transmission of HIV-1 is initiated by the replication of one or a small number of virions that penetrate the vaginal or rectal mucosa 26 . The FcRn-mediated anatomical localization of bnAbs to the rectal mucosa may more effectively block penetration at this site of entry. This localization, combined with the quantitative effects of FcRn on serum IgG levels, explains how increasing the affinity for FcRn improves bnAb efficacy. Notably, FcRn expression has also been reported in the female genital tract 27 : FcRn knockout in this previous paper was associated with decreased IgG-mediated protection against intravaginal herpes simplex virus (HSV-2) challenge. Because the FcRn knockout effects are global, it is unclear whether this effect was mediated through a systemic or mucosal effect; nonetheless, together, these studies are complementary and support the idea that FcRn mediates mucosal protection by IgG. The potential role of FcRn at other mucosal sites is further supported by the observation that VRC01 accumulates in vaginal tissues and localizes to the basal and parabasal layers of the vaginal epithelium, similarly to FcRn, as determined by immunohistochemistry (Extended Data  Fig. 6 ). Presumably, FcRn-mediated transport increases the monoclonal antibody levels in this tissue, where it might similarly confer protection against infection.
Altering the pharmacokinetic profile of antibodies by increasing halflife and tissue localization has practical implications for the use of passive monoclonal antibody administration for immunoprophylaxis and therapy. One concern about the use of such monoclonal antibody mutations is whether they might elicit immune responses to the FcRn-binding mutation. We found no evidence of increased antibody responses to VRC01-LS or specifically to the LS mutation relative to VRC01 (Extended Data Fig. 7 ). Because VRC01 is human and xenogeneic to nonhuman primates, such questions about immunogenicity must eventually be evaluated in humans. In this regard, at least one human monoclonal antibody with an FcRn-binding-site mutation (motavizumab-YTE; M252Y / S254T / T256E) has been tested in healthy human adults and did not induce an appreciable increase in an anti-drug antibody response compared with the wild-type antibody 28 . Potent bnAbs with increased FcRn binding can be retained in relevant tissues for extended periods, decreasing the necessary amount of antibody, as well as the frequency of injections, thereby making the treatment or prevention of viral infections by passive antibody transfer more feasible than at present and broadly applicable. In addition to its potential importance for the optimization of passive immune prevention of HIV-1 infection of humans, this mechanism is also likely to be relevant to antibody-mediated protection against other mucosal pathogens such as rotavirus, poliovirus, norovirus and influenza virus.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Generation and characterization of VRC01 Fc mutants. The Fc mutations used in this study are indicated in Fig 1a. The amino acid positions are numbered according to the EU index of human IgG1 (ref. 30) . Mutations were introduced to the heavy chain gene of VRC01 by site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Mammalian expression plasmids encoding the heavy and light chain genes were transiently co-transfected into the human embryonic kidney cell line 293F, and the supernatant was harvested 5 days later. The monoclonal antibodies were purified from the supernatant by Protein G column chromatography (GE Healthcare).
The glycosylation patterns of VRC01 and VRC01-LS were analysed by using nanoLC-ESI-MS/MS (nano liquid chromatography electrospray ionization mass spectrometry) peptide sequencing technology. In brief, each solution sample was cleaned and digested in-gel with sequencing grade modified trypsin (Promega). The resultant peptide mixture was analysed by an LC-ESI-MS/MS system, in which high performance liquid chromatography (HPLC) with a 75-mm (inner diameter) reverse phase C18 column was coupled in-line with an ion trap mass spectrometer (Thermo Scientific). Comparing the glycosylation patterns of VRC01 and VRC01-LS by mass spectrometry, we focused on the glycan at amino acid position N297, which is the single N-glycosylation site in the Fc region of IgG1 isotype antibodies (such as VRC01). A very similar pattern of complex glycan configuration was noted for both monoclonal antibodies (Extended Data Table 3 ). G1F (GalGlcNAc 2 Man 3 GlcNAc 2 Fuc) and G0F (GlcNAc 2 Man 3 GlcNAcFuc) are the major glycosylation species found in both VRC01 and VRC01-LS. While quantitative differences were noted in some glycan species, these differences represent small changes and fall within the limits of the expected experimental variability between preparations. More importantly, the LS mutation neither generated nor removed additional potential N-linked glycosylation patterns observed in VRC01. ELISA. RSC3 ELISAs were used to analyse IgG binding. ELISA plates (96 well) were coated with 2 mg ml 21 RSC3 in PBS, incubated at 4 uC overnight and blocked with PBS containing 5% BSA at room temperature for 1 h. Serial dilutions of each monoclonal antibody in 2.5% BSA in PBS were added to the plates and incubated at room temperature for 1 h. Horseradish peroxidase (HRP)-conjugated anti-human IgG, Fcc-specific (Jackson ImmunoResearch Laboratories), was added and incubated at room temperature for 1 h. Tetramethylbenzidine (TMB, Sigma) HRP substrate was added to each well, and the absorbance of the yellow colour that developed after adding 0.5 M H 2 SO 4 was measured at 450 nm.
The binding of IgG to human FcRn or human Fcc receptors was examined as follows. His-tagged human FcRn was purified as previously described 31 , and Histagged human FccRIIIa, FccRIIa and FccRIIb were purchased from R&D Systems. Nickel-coated plates (96 well, Thermo Scientific) were coated with 2 mg ml 21 Histagged human FcRn or human Fcc receptor and incubated at room temperature for 1 h. The ELISA was performed as described above. To examine the binding of monoclonal antibodies to human FcRn at pH 6.0, PBS at pH 6.0 was used instead of PBS at pH 7.4. EC 50 determination for human FcRn binding was calculated by computer-assisted nonlinear fitting using GraphPad Prism (Graphpad Software).
VRC01 and its mutants were quantified as follows. ELISA plates (96 well) were coated with 2 mg ml 21 RSC3 in PBS, incubated at 4 uC overnight and blocked with PBS containing 5% BSA at room temperature for 1 h. Sera were diluted in 2.5% BSA in PBS and added to the plate and incubated at room temperature for 1 h, and the ELISA was carried out as described above. Purified monoclonal antibodies were used as a standard, and the limit of detection was 0.4 ng ml
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. Anti-VRC01 antibody responses were evaluated as follows. The sera from macaques that had been administered VRC01 or VRC01-LS were added to 96-well ELISA plates coated with 2 mg ml 21 VRC01 or VRC01-LS. To test VRC01-LS -specific antibody responses, the sera from the two groups were absorbed with 20 mg ml 21 VRC01, and the ELISA was carried out against VRC01-LS. The sera were diluted with TBS containing 5% skim milk, 2% BSA and 0.05% Tween 20, and the ELISA was performed as described above. Neutralization assays. Antibody-mediated neutralization of pseudotyped HIV-1 isolates was measured using the TZM-bl luciferase reporter gene assay as described previously [32] [33] [34] . The target baseline infection level was ,200,000 relative light units. Neutralization curves were fit using a five-parameter hill-slope equation as described previously 34 . The concentrations of VRC01 and its mutants that were required to inhibit infection by 50% or 80% are reported as 50% or 80% inhibitory concentrations (IC 50 or IC 80 ), respectively. Biacore binding assays. For surface plasmon resonance analysis, human FcRn and human FccRIIIa (5 mg ml 21 in 10 mM acetate, pH 5.5, for 10 min at a 10 ml min 21 flow rate) were immobilized on a Biacore CM5 Sensor Chip to an immobilization level of ,500 response units (RU). VRC01 and its Fc mutants were injected for 2 min at various concentrations (0.01-10 mM) and allowed to dissociate for 3 min at a 50 ml min 21 flow rate. The human FcRn surface was regenerated by two sequential injections of 13 PBS (pH 7.4) for 1 min at an 80 ml min 21 flow rate, while the human FccRIIIa surface was regenerated with two sequential injections of 10 mM glycine (pH 2.1). All binding affinities were calculated using a 1:1 Langmuir fitting equation and Scrubber 2 (BioLogic Software), with an average value determined over the range of concentrations measured. Animals. mFcRn 2/2 hFcRn(276) Tg/Tg mice were obtained from Jackson Laboratories (stock number 004919). They were housed and bred in the animal facility of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases. Macaca mulatta animals of Indian origin and Macaca fascicularis were used in the non-human primate study. All animal experiments were reviewed and approved by the Animal Care and Use Committee of the VRC, and all animals were housed and cared for in accordance with local, state, federal and institutional policies in a facility accredited by the American Association for Accreditation of Laboratory Animal Care at the National Institutes of Health. Animal numbers per group in this study were chosen in accordance with previously published papers 13, 15, 16 . Animals were chosen and randomized based on age and weight. ADCC assay. ADCC assays were performed using a fluorescence activated cell sorting (FACS)-based method, as previously described 20 . Briefly, HIV-IIIB-infected CEM NK R -CCR5 cells were used as target cells and human peripheral blood mononuclear cells were used as effector cells. Target cells were double-stained with the fluorescent dyes PKH26 (Sigma) and carboxyfluorescein succinimidyl ester (CFSE; Invitrogen). Target cells (10,000) and serially diluted monoclonal antibody were added to each well of a 96-well plate, mixed thoroughly and incubated at room temperature for 15 min. Effector cells (500,000) were added to each well and mixed thoroughly. The plate was centrifuged for 3 min at 400 r.p.m. and incubated at 37 uC in a 5% CO 2 incubator for 4 h. The cells were washed with PBS, fixed with 1% paraformaldehyde in PBS, and stored at 4 uC overnight. The percentage of CFSE 2 cells within the PKH26 hi population was obtained by using an LSR-II flow cytometer (BD Biosciences) and FlowJo software (TreeStar). Non-stained and single-stained targets were included in every experiment to compensate for single-stained CFSE and PKH26 emissions. Transcytosis assay. Assessments of transcytosis of VRC01 and its Fc mutants were performed as previously described for IgG 35 . Briefly, MDCK cells were transfected to express human b 2 -microglobulin and human FcRn or vector controls and were grown to confluence in DMEM containing 10% FBS and 1% penicillin and streptomycin on 12-mm transwells with a pore size of 0.4 mm (Corning) and allowed to polarize for 96 h. Twelve hours before the commencement of transcytosis experiments, the medium was changed to serum-free medium without antibiotics. On the day of the experiment, the measured transepithelial resistance ranged between 150 and 200 Vcm 2 . Transwells were incubated in Hank's balanced salt solution (HBSS), pH 7.4, for 20 min followed by equilibration at 36 uC and 5% CO 2 in a 12-well plate containing HBSS, pH 6.0, in the input chamber and HBSS, pH 7.4, in the output chamber. pH 6.0-adjusted VRC01 variants at varying concentrations in HBSS were then directly added to the input chamber. After incubating for 2 h at 36 uC and 5% CO 2 , the medium in the output chamber was collected, and the monoclonal antibody concentrations were quantified by ELISA. Mycoplasma-free stocks of transfected MDCK cells using the Venor GeM Mycoplasma Detection Kit (Sigma, MP0025) were maintained as aliquots and regularly thawed for use every 3-4 weeks. Pharmacokinetic experiments in rhesus macaques. Female Indian rhesus macaques weighing between 2.9 and 6.7 kg were randomly assigned to groups according to body weight (four macaques per group for VRC01 and VRC01-LS, and two macaques per group for VRC01-IHH) and were intravenously injected with 10 mg kg 21 monoclonal antibody. Blood was collected before injection on day 0, at 30 min and 6 h after injection, and at 1, 2, 4, 7, 14, 21 and 28 days after injection. The concentration of each monoclonal antibody was quantified by ELISA. Pharmacokinetic parameters were calculated with a two-compartment model using the WinNonlin software (Pharsight). Immunohistochemical staining. All staining procedures were performed as previously described 36 , using 5-mm tissue sections mounted on glass slides. Tissues were deparaffinized and rehydrated in deionized water. Heat-induced epitope retrieval was performed using a water bath (98 uC) in EDTA Decloaker (Biocare Medical), followed by cooling to room temperature. Tissue sections were then blocked with Sniper blocking reagent (Biocare Medical) for 30 min at room temperature. RSC3-biotin was diluted at 1:100 in TNB (0.1 M Tris-HCl, pH 7.5, 0.1 M NaCl and 0.05% Tween 20 with DuPont Blocking Reagent) and incubated overnight at 4 uC. After the RSC3-biotin incubation, the sections were washed with PBS containing 0.1% Tween 20 and then incubated with anti-biotin antibody conjugated to alkaline phosphatase in TNB for 2 h at room temperature. After the incubation with anti-biotin antibody, the sections were washed with PBS containing 0.1% Tween 20. Signal was detected with the Warp Red Chromogen Kit (Biocare Medical). The sections were counterstained with Harris Hematoxylin (Surgipath), dehydrated rapidly in a gradient of ethanols and mounted with Permount (Fisher Scientific). Stained sections were examined by light microscopy at ambient temperatures. Light micrographs were RESEARCH LETTER
